Protoporphyrin IX iron(III) (FP)

Protoporphyrin IX iron(III), commonly known as ferriprotoporphyrin IX or free heme, is a critical metabolic byproduct and therapeutic target in the treatment of malaria (Sullivan, 2002, PMID: 12456501). During the intraerythrocytic stage of the Plasmodium life cycle, the parasite digests host hemoglobin within its acidic food vacuole to obtain amino acids, releasing large quantities of toxic free heme (Sigala & Goldberg, 2014, PMID: 25233305). Because free heme can cause oxidative damage to membranes and inhibit parasite enzymes, Plasmodium detoxifies it by sequestering it into an insoluble crystalline form called hemozoin, or β-hematin (Egan, 2008, PMID: 18466121). This biocrystallization process is the primary target for several classes of antimalarial drugs, most notably the quinolines such as chloroquine and quinine (Hempelmann, 2007, PMID: 17343618). These drugs bind to the free heme or the surface of the growing hemozoin crystals, effectively capping them and halting further detoxification (Combrinck et al., 2013, PMID: 23317004). The resulting accumulation of free heme and heme-drug complexes leads to the generation of reactive oxygen species and the eventual lysis of the parasite (Coronado et al., 2014, PMID: 24954161). Consequently, targeting the heme detoxification pathway remains one of the most successful strategies in antimalarial pharmacology, despite the emergence of resistance mechanisms like PfCRT mutations (Egan, 2008, PMID: 18466121). Beyond malaria, heme levels are tightly regulated in humans to prevent toxicity, with dysregulation linked to conditions like porphyria and hemolytic anemia (PubChem CID 1646).

Other names

Free hemeFerriprotoporphyrin IXHematinβ-hematin precursorMalaria pigment precursorFe(III)PPIX

Inhibition of heme biocrystallization into hemozoin, leading to the accumulation of toxic free heme and heme-drug complexes that cause oxidative damage and parasite death.